Sight Sciences, Inc. (SGHT) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
4.31
↑+21% vs avg
5yr avg: 3.58
30Y Low2.1·High6.5
ROE
↑
-50.7%
↓+7% vs avg
5yr avg: -54.4%
30Y Low-88%·High-40%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SGHT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sight Sciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $286M | $414M | $182M | $251M | $584M | $835M | — | — | — |
| Enterprise Value | $235M | $362M | $102M | $148M | $434M | $608M | — | — | — |
| P/E Ratio → | -7.15 | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.69 | 5.35 | 2.28 | 3.10 | 8.19 | 17.05 | — | — | — |
| P/B Ratio | 4.31 | 6.47 | 2.09 | 2.09 | 3.65 | 3.60 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SGHT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.68 | 1.28 | 1.83 | 6.09 | 12.42 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
SGHT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Sight Sciences, Inc. earns an operating margin of -48.0%. Operating margins have expanded from -70.7% to -48.0% over the past 3 years, signaling improving operational efficiency. A negative ROE of -50.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.2% | 86.2% | 85.5% | 85.3% | 82.7% | 82.4% | 66.7% | 72.0% | 69.0% |
| Operating Margin | -48.0% | -48.0% | -63.3% | -70.7% | -117.7% | -105.2% | -116.5% | -103.0% | -189.9% |
| Net Profit Margin | -49.7% | -49.7% | -64.5% | -68.5% | -120.9% | -128.6% | -125.5% | -110.8% | -189.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -50.7% | -50.7% | -49.6% | -39.6% | -44.0% | -87.9% | — | — | — |
| ROA | -29.8% | -29.8% | -33.3% | -29.3% | -35.0% | -35.7% | -67.0% | -133.2% | -176.6% |
| ROIC | -274.4% | -274.4% | -302.9% | -311.8% | -803.0% | -686.3% | — | — | -1129.9% |
| ROCE | -32.0% | -32.0% | -35.9% | -32.8% | -36.3% | -31.2% | -74.1% | -168.1% | -275.0% |
SGHT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $92M exceeds total debt of $41M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.64 | 0.64 | 0.46 | 0.29 | 0.22 | 0.15 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.80 | -0.91 | -0.85 | -0.94 | -0.98 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -7.21 | -7.21 | -10.00 | -9.25 | -18.30 | -13.38 | -13.41 | -12.19 | — |
Net cash position: cash ($92M) exceeds total debt ($41M)
SGHT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Sight Sciences, Inc.'s current ratio of 10.22x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 9.52x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 13.29x to 10.22x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.22 | 10.22 | 9.04 | 13.29 | 11.77 | 20.52 | 7.58 | 3.82 | 2.47 |
| Quick Ratio | 9.52 | 9.52 | 8.63 | 12.65 | 11.43 | 20.26 | 7.30 | 3.51 | 2.31 |
| Cash Ratio | 8.34 | 8.34 | 7.78 | 11.27 | 10.38 | 19.30 | 6.60 | 2.89 | 1.46 |
| Asset Turnover | — | 0.67 | 0.56 | 0.49 | 0.33 | 0.17 | 0.38 | 0.76 | 0.93 |
| Inventory Turnover | 1.38 | 1.38 | 1.83 | 1.51 | 2.02 | 2.48 | 3.54 | 2.92 | 4.81 |
| Days Sales Outstanding | — | 45.98 | 49.29 | 64.34 | 77.51 | 64.93 | 70.82 | 64.00 | 87.98 |
SGHT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sight Sciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $52M | $50M | $49M | $48M | $48M | $47M | $34M | $32M |
Peer Comparison
Compare SGHT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SGHTYou | $286M | -7.1 | — | — | 86.2% | -48.0% | -50.7% | -274.4% | — |
 GKOS | $8B | -40.9 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 ATRC | $1B | -115.8 | 77.7 | 29.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 MASI | $9B | -63.8 | 27.7 | 47.3 | 61.9% | 20.5% | -17.1% | 16.5% | 1.6 |
 TNDM | $1B | -6.1 | — | — | 52.3% | -7.7% | -97.9% | -10.0% | — |
 ABT | $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 SYK | $113B | 35.0 | 20.3 | 26.3 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See SGHT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SGHT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SGHT vs GKOS
Side-by-side business, growth, and profitability comparison vs Glaukos Corporation.
Start ComparisonSGHT — Frequently Asked Questions
Quick answers to the most common questions about buying SGHT stock.
What is Sight Sciences, Inc.'s P/E ratio?
Sight Sciences, Inc.'s current P/E ratio is -7.1x. This places it at the 50th percentile of its historical range.
What is Sight Sciences, Inc.'s ROE?
Sight Sciences, Inc.'s return on equity (ROE) is -50.7%. The historical average is -54.4%.
Is SGHT stock overvalued?
Based on historical data, Sight Sciences, Inc. is trading at a P/E of -7.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Sight Sciences, Inc.'s profit margins?
Sight Sciences, Inc. has 86.2% gross margin and -48.0% operating margin.